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HCCK the Bmax values being 121550±45550 and 84880±5380 sites/cell,
respectively. From these data the calculated KD values were 1.1±0.06
(HFLS) and 3.1±1.7 (HCCK) nM. Inhibition curves were performed with
antagonists (1 pM-1mM) or unlabelled BK at the [3H]BK binding (1.5 nM).
Ki values for BK were 0.93±0.12 (HFLS) and 0.83±0.12 (HCCK) nM.
Both antagonists displayed high afﬁnity values: MEN16132 Ki values of
1.35±0.05 and 1.75±0.35 nM in HFLS and HCCK, respectively, and icati-
bant was 3- to 5-fold less potent, Ki values being 4.6±1.7 and 8.8±2.9 nM.
BK induced IP accumulation both in HFLS (EC50 0.73±0.08 nM) and
HCCK (EC50 0.64±0.05 nM), and the induced maximal effect was 11±3
(HFLS) and 15±1.5 (HCCK) fold over the basal response. The antag-
onists potency was evaluated by preincubating cells with MEN16132
or icatibant at different concentrations (0.1 nM-10 mM) for 15min before
the agonist concentration-response curve (0.03 nM-100mM). Both antag-
onists displayed a concentration-dependent antagonism, by shifting to the
right the BK curve, but MEN16132 displayed a greater potency in respect
to icatibant. The calculated pKB values were 9.93±0.09 (HFLS) and
10.44±0.16 (HCCK) for MEN16132, and 8.1±0.03 (HFLS) and 8.2±0.16
(HCCK) for icatibant.
Conclusions: This is the ﬁrst study quantifying B2 receptors, the afﬁnity
and potency of BK and its antagonists in HCCK. Current data highlight
the pharmacological proﬁle of MEN16132 as a very potent bradykinin
antagonist, in respect with icatibant, both in HFLS and HCCK.
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Purpose: Our principal objective is to deﬁne potential cellular and
molecular interactions between inﬁltrating mast cells/mast-cell derived in-
ﬂammatory mediators and resident human synovial ﬁbroblasts ultimately
contributing to disease pathophysiology.
Methods:
1. Cultured human synovial ﬁbroblasts (HSF) were obtained from
osteoarthritis-affected synovial membranes.
2. Western and Northern blot analyses were used to measure protein
and mRNA expression, respectively.
3. Transient transfection assays were employed to express activated
signaling molecules and/or dominant negative mutants and to analyze
the reporter luciferase activity. A Mek1/2 inhibitor is also included in
this reporter luciferase activity study.
4. Prostaglandin E2 and leukotriene B4 levels were quantiﬁed by ELISA.
5. Statistical analyses included Student’s T-test and ANOVA.
Results:
1. Leukotriene B4 stabilized cyclooxygenase-2 mRNA and cyclooxygen-
ase-2 protein levels in Il-1b-treated human synovial ﬁbroblasts, leading
to the increase of prostaglandin E2 production.
2. Leukotriene B4 stabilized cyclooxygenase-2 mRNA on post-
transcriptional level through the cyclooxygenase-2 mRNA 3′-UTR re-
gion in Il-1b-treated human synovial ﬁbroblasts. There is no transcrip-
tional regulation in this stabilization effect of leukotriene B4.
3. Leukotriene B4 exerts this stabilization through Raf/MEK1/ERK1/2
signaling pathway in Il-1b-treated human synovial ﬁbroblasts.
4. The AU-containing proximal region of cyclooxygenase-2 mRNA 3′-
UTR is more important for this stabilization effect of leukotriene B4
in Il-1b-treated human synovial ﬁbroblasts than more distal AU rich
sequences.
Conclusions: The pathogenic mechanisms responsible for arthritis re-
main poorly understood both systemically and in the microenvironment of
the diarthrodial joint. Mast cells are detected in the synovial membrane of
osteoarthritis patients. We demonstrate the potential cellular and molec-
ular interactions between mast cells and mast-cell derived inﬂammatory
mediators and resident human synovial ﬁbroblasts. We hypothesize that
mast-cell derived leukotrienes contribute to synovial inﬂammation through
stabilization of synoviocyte cyclooxygenase-2 expression.
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Purpose: Inﬂammation plays an important role in promoting articular car-
tilage damage in joint diseases such as osteoarthritis (OA). Chondrocytes
and synovial ﬁbroblasts (SFs) are involved in joint inﬂammation by releas-
ing biochemical mediators (NO, prostaglandins) and pro-inﬂammatory
cytokines which lead to the decrease of chondrocyte anabolic activity
and the increase of extracellular matrix degradation. Therefore, to prevent
cartilage damage, therapies should aim both to enhance chondrocyte
anabolic activity and to control inﬂammation. Electromagnetic ﬁelds
(EMFs) stimulate anabolic activities in cartilage explants and prevent the
catabolic effect of the inﬂammatory cytokine Il-1. In vivo EMFs retard the
development of OA lesions in guinea pigs; in humans they have been
successfully used for the treatment of OA. Adenosine is known to reduce
inﬂammation in several models by interacting with four receptors (A1,
A2A, A2B and A3). The role of adenosine for managing joint inﬂammation
has been recently documented and drugs with adenosine A2A receptor
agonist activity have shown chondroprotective effects. The aim of this
study was to investiga the potential anti-inﬂammatory activities of EMFs
by the characterization of their effects on adenosine receptors in bovine
chondrocytes and SFs. The functional interaction among adenosine A2A
analogs and EMFs in SFs was analyzed by evaluating the production of
cAMP, an intracellular mediator, the release of prostaglandin E2 (PGE2)
and cyclooxygenase-2 (COX-2) expression.
Methods: Chondrocytes and SFs isolated from bovine articular joints
were cultured in vitro. The effects of EMFs (1.5 mT, 75Hz) on adenosine
receptors were investigated by saturation and competition binding experi-
ments. Adenylyl cyclase assays were performed to evaluate cAMP levels
induced by the A2A agonist, CGS 21680 (2-[p-(2-carboxyethyl)-phenetyl-
amino]-5′-N-ethyl-carboxamido adenosine) and the A2 agonist, NECA (5′-
N-ethyl-carboxamido adenosine) in the absence and in the presence of
EMFs. CGS 21680 and NECA were added to SFs untreated or treated
with TNF-alpha (10 ng/ml) in the absence or in the presence of EMFs.
PGE2 release was measured by immunoassay and COX-2 expression
was evaluated by RT-PCR.
Results: EMFs evoke the upregulation of the A2A and A3 receptors in
both SFs and chondrocytes. The increase in A2A receptor density (1.9 and
2.4 folds, p< 0.01 respectively in chondrocytes and SFs) was associated
to an increase in cAMP levels indicating the functionality of the receptors
in EMF-exposed cells. TNF-alpha stimulated PGE2 release in SFs. CGS
21680 and NECA signiﬁcantly inhibited PGE2 production respectively of
49% and 55%; EMFs inhibited PGE2 release of 63% (vs. TNF-alpha,
p< 0.01) and strongly enhanced the inhibition induced by the agonists.
Modiﬁcation of COX-2 expression mirrored changes in PGE2 levels.
Conclusions: This study supports anti-inﬂammatory activity of EMFs
mediated by an up-regulation of A2A receptors and shows a molecular
action mechanism by which EMFs act. The in vitro EMF anti-inﬂammatory
activity is consistent with the decrease in inﬂammatory cytokines expres-
sion in the articular cartilage of OA animals. Noteworthy, the biophysical
modulation of adenosine pathways has been used in humans as a
therapeutic intervention to control the inﬂammatory microenvironment in
in arthroscopic procedures.
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Purpose: The production of inﬂammatory mediators may contribute to
osteoarthritis (OA) pathology. High mobility group box chromosomal pro-
tein 1 (HMGB1) acts as a pro-inﬂammatory cytokine in a wide range of
cells and binds to the receptor for advanced glycation products (RAGE), a
pathway leading to catabolic responses in articular tissues. Of particular
interest in the regulation of inﬂammatory and catabolic processes is the
